Biocon's 4 global businesses include generics, biosimilars, research services and novel biologics. (Image Source: Unsplash) Show Quick Read Summary is AI Generated. Newsroom Reviewed

On Tuesday, Biocon Ltd. said its unit has received approval from the US health regulator for a genetic anti-bacterial medication. The approval was given to Biocon’s unit in partnership with Carnegie Pharmaceuticals LLC

"This is to inform you that Biocon Pharma Ltd., a wholly owned subsidiary of the Company, in partnership with Carnegie Pharmaceuticals LLC, received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for the ANDA for Rifaximin Tablets, 550 mg," the company informed the exchanges.

Rifaximin tablets are indicated for reducing the risk of overt hepatic encephalopathy (

See Full Page